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bc13, a ubiquitin-conjugating enzyme (Ubc), re-
quires the presence of a Ubc variant (Uev) for
polyubiquitination. Uevs, although resembling
Ubc in sequence and structure, lack the active site cys-
teine residue and are catalytically inactive. The yeast Uev
(Mms2) incites noncanonical Lys63-linked polyubiquiti-
nation by Ubc13, whereas the increased diversity of Uevs
in higher eukaryotes suggests an unexpected complica-
tion in ubiquitination. In this study, we demonstrate that
divergent activities of mammalian Ubc13 rely on its pair-
ing with either of two Uevs, Uev1A or Mms2. Structurally,
U
 
we demonstrate that Mms2 and Uev1A differentially
modulate the length of Ubc13-mediated Lys63-linked
polyubiquitin chains. Functionally, we describe that
Ubc13–Mms2 is required for DNA damage repair but
not nuclear factor 
 
 
 
B (NF-
 
 
 
B) activation, whereas
Ubc13–Uev1A is involved in NF-
 
 
 
B activation but not
DNA repair. Our ﬁnding suggests a novel regulatory
mechanism in which different Uevs direct Ubcs to diverse
cellular processes through physical interaction and alter-
native polyubiquitination.
 
Introduction
 
Protein modification by ubiquitin (Ub) is a fundamental post-
translational modification event that serves as a signaling func-
tion in diverse biological processes, including stress responses,
cell cycle progression, oncogenesis, and antigen presentation
(Pickart, 2001b). The ubiquitination of a protein substrate in-
volves the formation of an isopeptide bond between a substrate
lysine residue and the COOH-terminal carboxyl group of Ub
Gly76. This reaction is accomplished through the sequential
actions of several classes of enzymes. A Ub-activating enzyme
(Uba or E1) hydrolyzes ATP and forms a high-energy thioester
between a cysteine of its active site and the COOH terminus of
Ub. Activated Ub is then passed on to a Ub-conjugating en-
zyme (Ubc or E2), which forms thioester-linked complexes
with Ub in a similar fashion. Next, Ub is covalently attached to
the substrate protein by a Ub ligase (E3). The lysine residues
within Ub itself may also serve as substrates, leading to the for-
mation of poly-Ub chains (Chau et al., 1989); this poly-Ub
chain assembly may be facilitated by a recently identified E4
(Koegl et al., 1999).
Most organisms have only one E1 enzyme, whereas all
organisms have many E2 and E3 enzymes. All the known E2s
belong to a single family, containing a conserved catalytic core
domain harboring the active site cysteine residue (Pickart,
2001b). On the other hand, many known E3s belong to several
different protein families, including HECT, RING (Pickart,
2001a), and U-box (Hatakeyama and Nakayama, 2003). The
large number of E3s is consistent with the observation that the
E3 acts as the primary substrate recognition factor in the ubiq-
uitination reaction, whereas the E2 is thought to be involved in
the reaction largely through its association with a given E3.
Poly-Ub chains attached to a substrate can also be linked
through different lysines within Ub, and it has become clear
that the signaling properties of ubiquitination depend on the
topology of poly-Ub chains. For example, it has been well es-
tablished that poly-Ub chains linked through Lys48 are the
principal signal to target a substrate for proteolysis by 26S
proteasomes, whereas Lys63-linked chains play a regulatory
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role in diverse signaling pathways in a nonproteolytic fashion
(Pickart, 2001b). The molecular basis for determining such
specificity in chain assembly and recognition, however, re-
mains poorly understood. So far only one E2, Ubc13, has been
shown to mediate the assembly of Lys63-linked poly-Ub
chains, and this activity requires a Ubc variant (Uev) as a co-
factor; neither Ubc13 nor Uev alone is able to promote Lys63
poly-Ub chains (Hofmann and Pickart, 1999; McKenna et al.,
2001). Uev is defined as a protein that resembles Ubc in struc-
ture and amino acid sequence, but does not contain a cysteine
residue in the presumptive active site, rendering the protein cat-
alytically inactive (Broomfield et al., 1998; Sancho et al.,
1998). The prototype Uev, Mms2, was first isolated and char-
acterized from the budding yeast 
 
Saccharomyces cerevisiae
 
and is required for error-free postreplication repair (PRR;
Broomfield et al., 1998). The crystal structure (Moraes et al.,
2001; VanDemark et al., 2001) and NMR analysis (McKenna
et al., 2001) of the Ubc13–Mms2 heterodimer show that Mms2
binds the acceptor Ub in an orientation that allows only Lys63,
and not Lys48, to approach the active site on Ubc13. Subse-
quent studies indicate that many other proteins contain Uev do-
mains. Collectively called the Uev family of proteins, they are
as ancient as the Ubc family of proteins (Villalobo et al., 2002)
and they are highly conserved in the eukaryotic kingdom, from
protists to human (Brown et al., 2002). Higher eukaryotes, in-
cluding plants and mammals, contain an increasing number of
Uev proteins (Wong et al., 2003), suggesting that the Uev fam-
ily of proteins may have evolved to increase diversity and se-
lectivity in Ub conjugation. Nevertheless, it remains unknown
whether these evolved Uev proteins are functionally redundant
or each plays a specific role in discrete cellular processes. We
addressed this question in the current study and found that
Mms2 and Uev1, two mammalian homologues of the yeast
Mms2, although sharing 
 
 
 
90% amino acid sequence identity
to each other in their core domain (Fig. 1) and both capable of
cooperating with Ubc13 to promote ubiquitination in vitro, are
involved in distinct biological activities in vivo. Specifically,
we demonstrated that Mms2 is required in Ubc13-dependent
DNA damage response but not NF-
 
 
 
B activation, whereas
Uev1A is involved in Ubc13-dependent NF-
 
 
 
B activation but
not DNA damage response. Thus, our study provides novel in-
sight that Uev family proteins may have evolved to differen-
tially regulate E2 functions in diverse cellular processes.
 
Results
 
Rationale and hypothesis
 
The central hypothesis to be tested in this study is that mamma-
lian cells have distinct responses to genotoxic and nongenotoxic
stresses, which are at least partially achieved by modulation of
Ubc activity through different Uevs. In particular, we propose
that Mms2 and Uev1 modulate Ubc13 activity via physical in-
teraction and recruitment of the distinct Ubc–Uev complexes
into different cellular processes. Yeast Mms2 is required for an
error-free mode of PRR to prevent spontaneous and damage-
induced mutagenesis and genome instability. It is now clear
that the yeast Ubc13–Mms2 complex targets proliferating cell
nuclear antigen (PCNA) for Lys63 chain assembly (Hoege et
al., 2002). In mammalian cells, a Ubc13–Uev complex was
found to be involved in TRAF6-mediated regulation of I
 
 
 
B ki-
nase (Deng et al., 2000) and Bcl10/MALT-mediated Lys63-
linked polyubiquitination of NEMO/IKK
 
 
 
 (Zhou et al., 2004),
both leading to NF-
 
 
 
B activation. Hence, these two pathways
and additional activities related to these pathways were exam-
ined in the context of Ubc13 and Uev requirements.
 
Ubc13–Uev complex formation
 
A prerequisite for our hypothesis is that both Mms2 and Uev1
form stable complexes with Ubc13. Although the physical in-
teraction between Ubc13 and Uev has been reported in various
studies (Deng et al., 2000; Hofmann and Pickart, 1999; Mc-
Kenna et al., 2001), we decided to systematically test all three
Mms2 homologues found in human cells for their in vitro and in
vivo (in yeast cells) interactions. As shown in Fig. 2 A, bacterial
cell extracts from cells expressing GST-Mms2 (lane 2) and
GST-Uev1A (lane 3) were able to pull down purified recombi-
nant Ubc13 by GST affinity. In contrast, extracts from cells ex-
pressing GST alone (not depicted) or GST-Uev1B (Fig. 2 A,
lane 4) were unable to pull down detectable amounts of Ubc13.
To further confirm the in vitro data, yeast two-hybrid analysis
was performed by fusing Uev with the Gal4 DNA binding do-
main (Gal4
 
BD
 
) at the COOH terminus and Ubc13 with the Gal4
activation domain (Gal4
 
AD
 
) at the NH
 
2
 
 terminus. As shown in
Fig. 2 B, only Mms2-Gal4
 
BD
 
 and Uev1A-Gal4
 
BD
 
 were able to
interact with Gal4
 
AD
 
-Ubc13, resulting in simultaneous activa-
tion of 
 
P
 
GAL1
 
-HIS3 and 
 
P
 
GAL2
 
-ADE2, whereas Uev1B-Gal4
 
BD
 
was unable to interact with Gal4
 
AD
 
-Ubc13. To determine
whether the human Ubc13–Uev interaction is related to its bio-
logical functions in yeast cells, we attempted to functionally
Figure 1. Amino acid sequence comparison of yeast Mms2 and its human
homologues. The amino acid sequences are obtained from the following
sources: Mms2 (Broomfield et al., 1998); hMms2 (Xiao et al., 1998);
Uev1A and Uev1B (Rothofsky and Lin, 1997). The corrected Uev1A se-
quence as reported previously (Deng et al., 2000) was used for alignment. 
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complement the yeast 
 
mms2
 
 null mutant by expressing each
of the Uev-Gal4
 
BD
 
 constructs. Although expression of Mms2-
Gal4
 
BD
 
 and Uev1A-Gal4
 
BD
 
 was able to fully alleviate the severe
methyl methanesulfonate (MMS) sensitivity of 
 
mms2
 
 cells to
the wild-type level in a gradient plate assay, vector alone or the
Uev1B-Gal4
 
BD
 
 construct failed to rescue 
 
mms2
 
-deficient cells
from killing by MMS (Fig. 3). The lack of Uev1B activity in
yeast cells is likely due to the extended NH
 
2
 
-terminal sequence,
as deletion of the NH
 
2
 
-terminal 80–amino acid coding region
from 
 
UEV1B
 
 restores its DNA repair function in yeast (Xiao
et al., 1998) and the interaction with Ubc13 in a yeast two-
hybrid assay (unpublished data). Due to the lack of detection
of Uev1B–Ubc13 interaction, and our previous observation
(Franko et al., 2001) that mouse cells do not express the corre-
sponding 
 
Uev1B
 
 transcript, we decided to focus our attention on
the cellular functions of Mms2 and Uev1A in this study.
 
Ubc13 and Mms2, but not Uev1A, are 
involved in DNA damage response
 
To investigate the involvement of Ubc13 and Uevs in DNA re-
pair, we examined nuclear foci formation in response to DNA
damage. After DNA damage, many repair enzymes form stable
focal localizations near sites of DNA damage, depending on
the extent and type of damage. In particular, both Rad51 and
Mre11/Rad50/Nbs1 form DNA damage–induced nuclear foci,
but their distribution patterns are different (Maser et al., 2001),
which probably reflects their involvement in distinct recombi-
nation processes. We exposed NIH 3T3 and HepG2 cells to
various doses of DNA damaging agents such as MMS, UV,
and camptothecin (CPT), among which CPT treatment appears
to generate the most significant effect. CPT is a topoisomerase
I inhibitor, which converts a single-stranded DNA break into a
double-stranded break (DSB) at the replication fork (Ryan et
al., 1991; Tsao et al., 1993). Hence, CPT treatment serves as a
highly specific and predictable cause of DNA lesions.
Because Ubc13 and Uev are thought to be freely diffus-
ible between the cytoplasm and the nucleus, we attempted to re-
fine their localization by using an in situ cell fractionation pro-
cedure before fixation, which is a method frequently applied to
identify nuclear localization of DNA repair proteins (Andegeko
et al., 2001). After CPT treatment, nuclear foci positive for
Mre11 (Fig. 4 A), Rad51 (Fig. 4 B), and Ubc13 (Fig. 4, A and B)
immunoreactivity were observed after detergent extraction un-
der a stringent condition capable of releasing the diffuse Ubc13
nuclear staining in the S phase cells (not depicted). Surprisingly,
CPT-induced Ubc13 nuclear foci exhibit morphological distri-
butions distinct from both Rad51 and Mre11 foci. It was found
that within 1 h after CPT treatment, Rad51 and Mre11 foci be-
come very apparent in a significant number of cells as fine nu-
clear foci; however, Ubc13 foci were not apparent until nearly
4 h after CPT treatment. A time course analysis indicates that as
time progressed nearly all the cells retained Ubc13 immuno-
reactivity (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200502113/DC1). Furthermore, Ubc13 foci appeared as
Figure 2. Ubc13–Uev complex formation. (A) In vitro GST pull-down assay.
BL21(DE3)-RIL cells transformed with pGEX-hMMS2, pGEX-UEV1A, and
pGEX-UEV1B were grown and target gene expression was induced by
adding IPTG. Crude cell extracts were used to load GST affinity MicroSpin
columns and 40  g of purified hUbc13 was later added. The resulting elu-
tion was loaded onto an SDS-PAGE gel and stained with Coomassie blue.
Components used in each sample are indicated on the top. Lane 5 con-
tains 1  g of purified hUbc13 and lane 6 contains 1  g of purified GST,
as indicated by arrows. (B) Yeast two-hybrid analysis of Ubc13–Uev inter-
actions. Cotransformed plasmids are indicated on the left. The plates were
incubated for 3 d before taking the photograph. Only one representative
transformant from each combination is shown. Cells cotransformed with
pUev1B-G4BD/pGAD424 and pG4BD-1/pGAD-Ubc13 were also nega-
tive (not depicted).
Figure 3. Heterologous function of human UEV genes in yeast. WXY903
(mms2 ::HIS3) was transformed with various pUev-G4BD plasmids and
the transformants were compared with HK580-10D (wild type) in a gradi-
ent plate assay for their ability to complement the yeast mms2 defect.
Overnight cell cultures were printed on YPD (A) or YPD   0.025% MMS
(B) plates and incubated for 36 h before taking the photograph. The arrow
points toward higher MMS concentration. 
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punctuate structures distinctly larger than the fine granular foci
of either Rad51 or Mre11 and were colocalized with those of
BrdU incorporation (Fig. 4 C), implying that Ubc13 is involved
in DNA synthesis under DNA damage conditions. The punctu-
ate pattern of Ubc13 foci and BrdU incorporation agrees with a
previous finding (Sakamoto et al., 2001) that Rad51 nuclear foci
are distinct from the distribution pattern of BrdU incorporation
after CPT treatment.
Because mAbs raised against human Mms2 were unable
to distinguish Mms2 from Uev1, we studied their subcellular
localization by expressing either myc-tagged Mms2 or Uev1A
in 3T3 and HepG2 cells. Immunofluorescence study using
mAb 9E10 against c-myc showed that Mms2 and Uev1 were
distributed in both nucleus and cytoplasm regardless of DNA
damage treatment (Fig. S2, available at http://www.jcb.org/cgi/
content/full/jcb.200502113/DC1). However, after CPT treat-
ment and detergent extraction, nuclear foci containing Mms2-
myc were observed, and they were colocalized with endogenous
Ubc13 foci (Fig. 4 D). In contrast, Uev1A-myc was not found
in the nuclear foci of CPT-treated cells and cannot be colocal-
ized with those of Ubc13 (Fig. 4 E). These observations provide
strong evidence that the Ubc13–Mms2 complex is involved
in DNA damage repair, which is distinct from the Ubc13–
Uev1A complex.
 
Suppression of Ubc13 or Mms2 results 
in an increase in Rad51 foci formation
 
To further address whether the Ubc13–Mms2 and Ubc13–
Uev1A complexes play a role in protecting mammalian cells
from genomic instability under normal growth conditions, we
attempted to experimentally suppress target gene expression by
Figure 4. CPT-induced nuclear foci formation. ICC of 3T3 cells after CPT
treatment (5  M for 4 h) and in situ cell fractionation reveals Ubc13 nuclear
foci (4E11 as primary antibody and Alexa488 as secondary antibody).
These foci are compared, by merging images, with those of Mre11 (A),
Rad51 (B), and BrdU (C) and in 3T3 cells transfected with Mms2-myc (D),
Uev1A-myc (E), and Uev1A 30-myc (F) viewed by using specific primary
antibodies and the Alexa546 secondary antibody, except in C, in which
Alexa546 is directly conjugated with anti-BrdU. Bar, 5  m.
Figure 5. Spontaneous Rad51 nuclear foci formation after RNAi treatment.
(A) Western blot analysis of purified recombinant hMms2 (lane 1),
hUbc13 (lane 2), and 3T3 total cell extracts (lanes 3–7) using 4E11 (anti-
Ubc13) or 2H11 (anti-hMms2) as primary antibodies. Lanes 4–7 repre-
sent cultures transfected with various RNAi constructs as indicated. Note
that 2H11 (and other anti-hMms2 mAbs) detected only one band from
mammalian cell extracts, which corresponds to the migration of Mms2,
but was found to contain both Mms2 and Uev1A by mass spectrometry
(not depicted). (B–F) 4 d after transfection of 3T3 cells with the indicated
RNAi constructs against specific target genes, cells were stained with ei-
ther 4E11 (B and C) or 2H11 (D–F) plus Alexa488 to reveal Ubc13 and
Uev immunoreactivity, respectively. The same cells were also stained with
anti-Rad51 plus Alexa546 to reveal Rad51 nuclear foci and with DAPI to
reveal nuclei of all cells. Bar, 10  m. 
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an RNA interference (RNAi) technology (Yu et al., 2002) and
examine its effects on endogenous DNA damage, as measured
by spontaneous Rad51 and Mre11 nuclear foci formation. The
effects of this method were examined by Western blot analysis
using Ubc13 and Mms2/Uev1-specific mAbs. As shown in Fig.
5 A, transfection of mouse 3T3 cells with RNAi against Ubc13
(iUbc13) reduced target Ubc13 to an undetectable level (lane 7)
with no effect on Mms2/Uev1A expression. This suppression is
highly specific, as a single nucleotide mismatch (iUbc13m)
completely abolished the target gene suppression (Fig. 5 A,
lane 6). Transfection with iMms2 (Fig. 5 A, lane 4) or iUev1
(lane 5) resulted in partial reduction of 2H11 immunoreactivity;
the remaining immunoreactivity is presumably due to cross-
reaction of 2H11 to both Mms2 and Uev1. Similar results were
also obtained by immunocytochemical analysis (Fig. 5, D–F),
which together demonstrate that, like iUbc13, the suppression
of target genes by iMms2 and iUev1 was also highly efficient
and specific. Experimental ablation of either Ubc13 or Mms2 in
3T3 cells was accompanied by an increased number of cells ex-
hibiting Rad51 nuclear foci from a basal level of 
 
 
 
8 to 33 and
32%, respectively; the difference is consistent in three indepen-
dent experiments and statistically significant (P 
 
  
 
0.001; Fig.
5, C and E; and Table I). In contrast, cells transfected with
iUbc13m (Fig. 5, B and D) did not affect Rad51 foci formation,
suggesting that the induced Rad51 nuclear foci were indeed due
to the increased spontaneous DNA damage when Ubc13 or
Mms2 activity was compromised. As expected, iUev1 transfec-
tion did not result in an increased number of cells containing
Rad51 nuclear foci (Fig. 5 F and Table I), suggesting that Uev1
is not involved in DNA damage avoidance. It was noted that
within the experimental period, cell viability, doubling time,
and the percentage of Mre11-positive nuclei were not altered in
any of the aforementioned RNAi transfectants (unpublished
data). Thus, we conclude from the aforementioned observations
that Ubc13 and Mms2 are required to prevent endogenous DNA
damage and double strand break formation, whereas Uev1 is not
involved in this process. To our knowledge, this is the first ex-
perimental evidence that a mammalian Ubc13–Uev complex
protects cells from spontaneous DNA damage.
 
Suppression of Ubc13 or Uev1 reduces 
TRAF2- and TRAF6-mediated 
NF-
 
 
 
B activation
 
The TNF associated factors 2 and 6 (TRAF2 and TRAF6) are
involved in the signaling cascades initiated by TNF receptors,
Toll-like receptors, and several interleukin receptors (Sun and
Chen, 2004). Both TRAF2 (Shi and Kehrl, 2003) and TRAF6
(Deng et al., 2000) have been implicated as E3s for Ubc13-
mediated NF-
 
 
 
B activation; however, it remains unclear which
Uev is required for Ubc13 function in these signaling pathways.
To address this issue, we used synthetic small interference RNA
(siRNA) to specifically inhibit the expression of either Mms2
or Uev1. Because 2H11 monoclonal antibody recognizes both
Mms2 and Uev1, we verified the specificity of our targeting
siRNAs for either Mms2 or Uev1 by examining their effects in
knocking down the expressions of FLAG-Mms2 and/or myc-
Uev1A. As shown in Fig. 6 A, siRNA against Mms2 (lanes 2
and 8) or Uev1 (lanes 6 and 9) specifically inhibits its target
gene expression but does not display a cross inhibitory effect.
Consistent with our previous findings (Zhou et al., 2004),
siRNA-targeting Ubc13 significantly reduced TRAF2- and
TRAF6-stimulated NF-
 
 
 
B activation (Fig. 6 B). Moreover,
 
Table I. 
 
Percentage of Rad51 nuclear foci–positive cells after RNAi 
treatment
RNAi
Total cells
counted
Rad51-positive
nuclei SD
P with respect
to control
 
%
 
Ubc13m 1,010 8
 
 
 
 1.3 –
Ubc13 991 33
 
 
 
 2.5
 
  
 
0.001
Mms2 970 32
 
 
 
 2.5
 
  
 
0.001
Uev1A 1,011 8
 
 
 
 1.7 1.0
Figure 6. Ablation of Uev1A suppresses TRAF-induced NF- B activity
and NEMO polyubiquitination in 293T cells. (A) Western blot analysis con-
firms RNAi specificity and efficacy of target suppression. (B) Modulation
of IKK -, TRAF2-, and TRAF6-induced NF- B activity by ablation of
Ubc13, Uev1, or Mms2. The relative NF- B activity was calculated
against transfected cells without siRNA treatment. (C) Effects of Mms2 or
Uev1 ablation by siRNA on NEMO polyubiquitination. s, scrambled non-
specific siRNA; M, siMms2; U, siUev1. The arrow points to TRAF6. 
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siRNA-targeting Uev1 but not Mms2 inhibited TRAF2- and
TRAF6-stimulated NF-
 
 
 
B activation. This effect is apparently
specific for TRAF2- and TRAF6-dependent ubiquitination to ac-
tivate NF-
 
 
 
B because neither Ubc13 nor Uev1 silencing affected
IKK
 
 
 
-mediated NF-
 
 
 
B activation (Fig. 6 B). These results high-
light a specific role for Uev1 but not Mms2 in cooperating with
Ubc13 in activating the NF-
 
 
 
B pathway.
We have previously established that NEMO/IKK
 
 
 
 is a
cellular target of Lys63 polyubiquitination and that siRNA sup-
pression of Ubc13 abolishes NEMO polyubiquitination (Zhou
et al., 2004). To determine whether a Uev is required for
NEMO polyubiquitination and, more importantly, which Uev
plays such a role, we experimentally suppressed either Mms2
or Uev1 in HEK 293T cells by siRNA treatment and monitored
NEMO ubiquitination. As shown in Fig. 6 C, cells treated
with siRNA-targeting Uev1 (fifth lane) significantly reduced
NEMO ubiquitination. In contrast, suppression of Mms2 (Fig.
6 C, fourth lane) did not appear to have a significant effect on
NEMO ubiquitination compared with untreated or random
siRNA-treated cells. Due to the cross immunoreactivity of
2H11 to both Mms2 and Uev1, we were unable to quantita-
tively determine the efficacy of siRNA treatment in this experi-
ment, although siRNA against Mms2 or Uev1 variably reduced
2H11 immunoreactivity. Nevertheless, the result is consistent
with that of the NF-
 
 
 
B activity assay (Fig. 6 B) indicating that
only Uev1A, but not Mms2, is involved in the NF-
 
 
 
B activa-
tion via Lys63-linked polyubiquitination of NEMO.
 
Ubc13 and Uev1 are required for 
lipopolysaccharide (LPS)-induced 
NF-
 
 
 
B activation
 
The bacterial endotoxin LPS stimulates NF-
 
 
 
B activation in mi-
croglia (Bonaiuto et al., 1997). To determine the physiological
significance of the Ubc13–Uev complex in this pathway, we
monitored the nuclear translocation of the p65 subunit of NF-
 
 
 
B
in response to LPS in primary murine microglia cells. In un-
treated cells, p65 resided mainly in the cytoplasm, whereas upon
LPS treatment, p65 rapidly translocated into the nucleus (unpub-
lished data). As shown in Fig. 7, RNAi directed to reduce Mms2
did not affect p65 translocation to the nucleus after LPS treat-
ment. However, after LPS treatment, the number of microglia
nuclei containing significant p65 immunoreactivity was reduced
from nearly 100% to 
 
 
 
30% in cells transfected with RNAi con-
structs directed to reduce either Ubc13 or Uev1. This result indi-
cates that the activities of Ubc13 and Uev1A, but not Mms2, are
indeed required in the NF-
 
 
 
B signaling pathway.
 
Distinct Lys63 chain assembly activities 
between Mms2 and Uev1A
 
Given that both Uev1A and Mms2 are able to form a stable
complex with Ubc13 in vivo and in vitro, but their biological
functions are distinct, we hypothesize that the structural and
sequence differences between Uev1A and Mms2 are responsi-
ble for their distinct intracellular signaling pathways. As the
first step toward understanding how Uev1A and Mms2 are in-
volved in distinct cellular processes, we performed an in vitro
polyubiquitination activity assay using highly purified compo-
nents. To prevent E2 self-ubiquitination, a Ubc13 derivative
(Ubc13K92R) was used in the assay in combination with ei-
ther Mms2 or Uev1A. We have previously shown that both
Ubc13 and Ubc13K92R were able to form di-Ub conjugates
with equal efficiency (McKenna et al., 2001); however, neither
(Fig. 8, lanes 1 and 2) is able to carry out Ub chain assembly in
the absence of Uev. The addition of Mms2 could only support
di-Ub formation (Fig. 8, lane 3), in contrast to the poly-Ub for-
mation in the presence of Uev1A (Fig. 8, lane 5). Uev1A dif-
fers from Mms2 in two aspects, namely, the nonconserved
NH
 
2
 
-terminal 30 amino acids and 
 
 
 
10% sequence variation in
the remaining core domain (Fig. 1). To determine which dif-
ference is responsible for the observed poly-Ub versus di-
Ub formation, a 30-residue truncation was made in Uev1A
such that it resembled the core region of Mms2. Incubating
Uev1A
 
 
 
30 with Ubc13K92R resulted in only di-Ub formation
(Fig. 8, lane 4) in a manner similar to that observed with
the addition of Mms2. These observations suggest that the
additional NH
 
2
 
-terminal region of Uev1A is responsible for
Ubc13-mediated poly-Ub chain assembly through Lys63-
Gly76 linkage in vitro and that the differential polyubiquitina-
tion activity between Uev1A and Mms2 may play a role in
their distinct cellular functions.
Figure 7. Requirement of Ubc13 and Uev1A for LPS-induced p65 translo-
cation. Phase contrast, p65-ICC, and DAPI staining were performed 4 d
after transfection of mouse microglia with RNAi constructs as indicated,
followed by a 1.5-h exposure to 1  g/ml LPS and fixation. Merged im-
ages indicate colocalization of p65 immunostaining with nuclei. Identical
color adjustment was made to all merged images to enhance differential
colocalization. Bar, 10  m. 
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To address whether the NH2-terminal extension of
Uev1A dictates its cellular activity, we made a correspond-
ing Uev1A 30-myc construct, used it to transiently transfect
mouse 3T3 cells, and analyzed Uev1A 30-myc cellular local-
ization as previously described. Compared with Uev1A-myc,
Uev1A 30-myc did not appear to affect cellular distribution
before or after CPT treatment (Fig. S2, C and C ); however,
after detergent extraction, Uev1A 30-myc was found in the
nuclear foci and colocalized with Ubc13 (Fig. 4 F), which is
reminiscent of Mms2-myc (Fig. 4 D). Hence, the Uev1A core
domain behaves like Mms2 rather than the full-length Uev1A,
indicating that the NH2-terminal extension of Uev1A is proba-
bly a determinant of distinct Uev functions in vivo.
Discussion
Cells are facing two rather different types of environmental or
even endogenous stresses. Genotoxic stress threatens genome
stability, evokes cell cycle arrest, and induces DNA repair ca-
pacity, whereas cellular responses to nongenotoxic stresses
would be primarily to enhance cell survival and proliferation.
Covalent modification of target proteins by Ub and Ub-like
proteins is primarily involved in stress responses. It has been
reported recently that Ubc13 and its cognate Lys63 chain as-
sembly is required for two important stress responses, namely
DNA repair and NF- B activation. It is unclear, however,
how Ubc13 is involved in these two seemingly contradictory
pathways, as error-free PRR in yeast prevents spontaneous
and DNA damage–induced mutagenesis (Broomfield et al.,
1998) and a similar role in mammals would protect cells from
carcinogenesis. In contrast, activation of NF- B has been de-
scribed as a primary prosurvival and antiapoptotic response
and its activity has been linked to various cancers (Dixit and
Mak, 2002). Is the error-free PRR pathway conserved in
mammals? If it is, how do mammalian cells regulate the two
opposite pathways? The discovery of two yeast MMS2 homo-
logues in human cells, hMMS2 and UEV1 (Xiao et al., 1998),
provides a key to solve the paradox; however, the sequence
alignment and studies to date do not provide adequate infor-
mation as to which Uev is involved in which pathway. The
situation becomes even more complicated by the observation
that expression of either hMMS2 or UEV1 is able to rescue the
yeast mms2 mutant from killing by DNA damage, and that
both Mms2 and Uev1 are able to support Lys63 polyubiqui-
tination in vitro leading to NF- B activation (Deng et al.,
2000; Zhou et al., 2004). Here, we provide evidence that dif-
ferent Ubc13 activities are modulated by the two Uevs that act
as regulatory subunits for Lys63-mediated target modifica-
tion. This discovery may reveal a novel regulatory mechanism
for stress response.
Mms2 and DNA repair
Lower eukaryotes such as budding and fission yeasts contain a
single Ubc13 and its Uev partner, Mms2, which is essential for
error-free PRR (Broomfield et al., 1998; Brusky et al., 2000;
Brown et al., 2002). The Ubc13–Mms2 activity in yeast re-
sults in polyubiquitination of PCNA after its monoubiquitin-
ation at the Lys164 residue by the Rad6–Rad18 complex
(Hoege et al., 2002); PCNA modified by Lys63-linked poly-
Ub chain probably acts to switch a mode of damage tolerance
from translesion DNA synthesis and genome instability medi-
ated by mutagenic DNA polymerases (Stelter and Ulrich,
2003; Haracska et al., 2004) into an error-free PRR via sister
chromatid exchange and/or template switching (Pastushok and
Xiao, 2004). We demonstrate that the Ubc13–Mms2 complex
in mammalian cells probably inherits the same activity. First,
upon DNA damage, Ubc13 and Mms2 form nuclear foci with
newly synthesized DNA, suggesting that this complex resides
at or near the replication fork. Second, ablation of either
Ubc13 or Mms2 results in increased spontaneous DNA strand
breaks that induce Rad51 nuclear foci formation. Third, Mms2
and Ubc13 are retained in the S phase nucleus and colocalized
with PCNA (unpublished data). Finally, we also observed that
suppression of either Ubc13 or Mms2 results in slightly but
significantly increased sensitivity to killing by DNA damaging
agents and that the effect appears to be synergistic with simul-
taneous suppression of Rev3 (unpublished data), which is
reminiscent of the corresponding yeast mutant phenotypes
(Broomfield et al., 1998) and agrees with our previous obser-
vations (Li et al., 2002) that antisense suppression of hMMS2
results in phenotypes characteristic of error-free PRR defects.
In contrast, RNAi suppression of UEV1 does not share the
aforementioned phenotypes, nor is it found in S phase or dam-
age-induced nuclear foci. Hence, Uev1 is not involved in
DNA repair.
In summary, we found that UBC13 and MMS2 not only
protect mammalian cells from genome instability caused by en-
vironmental DNA damage but probably also prevent spontane-
ous DNA damage or replication fork collapse. When UBC13 or
MMS2 expression is compromised, cells probably accumulate
DSBs that in turn induce Rad51 nuclear foci formation. Our
observation that RNAi suppression of UBC13 and MMS2 only
induces Rad51 foci, but not Mre11 foci, indicates that DSBs
accumulated due to lack of Ubc13–Mms2 signaling would
have to be repaired by homologous recombination instead of
nonhomologous end joining, which is consistent with a previ-
ous observation that suppression of hMMS2 completely abol-
ishes UV-induced gene conversion (Li et al., 2002).
Figure 8. Ub chain building. Mms2 and
Uev1A were assayed for Ub chain building
activity using an in vitro ubiquitination reac-
tion. The components of the reaction are
noted in Materials and methods. The con-
centration of wild-type hUbc13 (Wt),
hUbc13K92R (K92R), hMms2, Uev1A, and
Uev1A 30 is 250 nM. The positions of free
Ub (Ub), di-Ub (Ub2), Ubc13-Ub (Wt-Ub),
and multi-Ub chains (Ubn) are indicated.
Major contaminant bands from the 
35S-Ub
preparation,  including the background
band comigrating with Ub2, are indicated
by an asterisk.JCB • VOLUME 170 • NUMBER 5 • 2005 752
Uev1 and NF- B activation
Before this study, it was unclear which Uev is involved in
TRAF2- and TRAF6-mediated NF- B activation because both
Mms2 and Uev1A are able to mediate the activity in vitro.
Our genetic analysis clearly demonstrates that it is Ubc13
and Uev1, but not Mms2, that are required for TRAF2- and
TRAF6-mediated NF- B activation, and that this activity is in
a step upstream of IKK but downstream or together with
TRAF2 and TRAF6. We further demonstrate that Uev1, but
not Mms2, is required for TRAF6-induced NEMO polyubiqui-
tination. This conclusion fits well with our previous observa-
tion that NEMO serves as the Lys63 chain target (Zhou et al.,
2004) and supports a recently proposed model (Sun et al.,
2004) in which the MALT1 oligomers bind to TRAF6, induce
TRAF6 oligomerization, and activate the E3 activity of TRAF6
to polyubiquitinate NEMO in the presence of Ubc13–Uev.
NF- B activation has been described as a prosurvival and
antiapoptotic response to bacterial and viral infections and
other environmental stresses. To address the physiological rele-
vance of Ubc13–Uev1 in stress response, we show that LPS-
induced NF- B activation in primary microglia cells requires
both Ubc13 and Uev1, but not Mms2. Constitutive activation
of NF- B is linked to cancers such as lymphoma and other hu-
man diseases (Dixit and Mak, 2002). Interestingly, human
UEV1 has been independently isolated by its ability to transac-
tivate the c-fos promoter (Rothofsky and Lin, 1997), and its
transcript level increases when SV40-transformed human em-
bryonic kidney cells undergo immortalization (Ma et al., 1998)
and decreases upon differentiation of the human colon carci-
noma cell line HT-29-M6 (Sancho et al., 1998). Furthermore,
the UEV1 mRNA level is elevated in all human tumor cell lines
examined compared with normal tissues (Xiao et al., 1998),
and the gene is located to chromosome 20q13.2, a region where
gene amplification is frequently observed in breast cancer
(Kallioniemi et al., 1994; Tanner et al., 1994; Brinkmann et al.,
1996) and other tumors (El-Rifai et al., 1998), as well as in vi-
rus-transformed immortal cells (Savelieva et al., 1997). These
observations collectively place UEV1 as a candidate protoon-
cogene. Indeed, we find that experimental overexpression of
UEV1A is sufficient to activate NF- B and inhibit apoptosis
(unpublished data). Conversely, the tumor suppressor gene
product CYLD appears to be a Lys63-specific deubiquitination
enzyme responsible for the removal of Ub from NEMO (Brum-
melkamp et al., 2003; Kovalenko et al., 2003). Hence, Uev1
serves as a regulatory subunit for Ubc13-mediated Lys63 chain
assembly and may be an excellent target for cancer therapy.
Mms2 versus Uev1A: a novel regulatory 
mechanism?
Protein ubiquitination and its related processes have been un-
veiled as a versatile mechanism to regulate protein activi-
ties in eukaryotes. Our data present a previously undescribed
mechanism by which different Uev molecules act as mutually
exclusive regulatory subunits of an E2 (Ubc13) to different
subcellular locations and/or to modify different target pro-
teins. Although Uev1A is required for NEMO polyubiquitina-
tion in the cytoplasm, mammalian Mms2, if it behaves like its
yeast homologue, may be involved in the ubiquitination of
PCNA in the nucleus.
Sensing and repairing DNA damage and NF- B activa-
tion are two rather distinct cellular processes and lead to oppo-
site cellular consequences. The former will arrest cell cycle
progress until DNA synthesis is complete or, if the damage is
too severe to repair, cause apoptosis, whereas the latter will pro-
mote cell survival and prevent apoptosis. How do cells sense
these different stresses and respond correctly? Our findings sug-
gest that the two highly conserved but functionally distinct
Uevs may play a central role in this decision-making process.
Three alternative, but not mutually exclusive, mechanisms may
be envisioned to achieve such regulation. First, Uev1A and
Mms2 may compete for binding to limited Ubc13 in the cell. It
is interesting to notice that structural analyses (McKenna et al.,
2001; Moraes et al., 2001; VanDemark et al., 2001) have shown
that the Ubc13–Uev heterodimer formation is in a 1:1 ratio, that
the binding affinity of Ubc13 for Mms2 and Uev1A is compara-
ble (McKenna et al., 2003), and that Mms2 and Uev1A are dis-
tributed in both the cytoplasm and the nucleus. Hence, Uev1A
can readily compete with Mms2 to prevent it from forming a
complex with Ubc13 in the nucleus. The fact that Uev1A is
found in the nucleus with no defined role described thus far sug-
gests that perhaps Uev1A competes with Mms2 in the nucleus
for binding to Ubc13 and acts as an antagonistic factor. This
possibility is particularly attractive because it would also ex-
plain its oncogenic property, as inhibition of error-free PRR in
yeast cells results in a massive increase in spontaneous mutagen-
esis (Broomfield et al., 1998), which would lead to genome in-
stability and tumorigenesis in mammals. Second, cellular Ubc13
may not be limited; however, it is not activated until binding to
a cognate Uev. This hypothesis predicts that Mms2 and Uev1A
are differentially activated depending on source of stress (e.g.,
genotoxic vs. nongenotoxic), and that the activated Ubc13–Uev
complex determines pathway specificity by either associating
with a specific E3 or other cellular components. The third possi-
ble mechanism is that Mms2 and Uev1 selectively activate tar-
get proteins through di- and polyubiquitination, respectively, as
demonstrated in this study. We have demonstrated that NEMO
is polyubiquitinated by Ubc13–Uev1A in vivo. In contrast, de-
spite repeated studies on monoubiquitinated PCNA (Kannouche
Figure 9. A working model of Ubc13–Uev functions in human cells.
This model is based on data and discussion presented in this paper as
well as some previous papers. Please note that a mammalian Rad5 homo-
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et al., 2004; Watanabe et al., 2004), it is not yet known whether
PCNA is di- or polyubiquitinated in vivo or in vitro. Neverthe-
less, we are able to show that the NH2-terminal extension of
Uev1A is probably the determinant of functional specificity and
that the core domain of Uev appears to play a default function in
DNA repair.
In summary, we demonstrate that Ubc13-mediated ubiq-
uitination can coordinate cellular responses to both DNA
damage as well as nongenotoxic stresses; its target selection
and mode of response (e.g., DNA repair or cell proliferation)
is determined not only by E3 proteins but also by a Uev as its
regulatory subunit. Hence, we propose that the Uevs serve as
an essential modulator of E2 ubiquitination activity. A working
model based on the aforementioned analyses is depicted in
Fig. 9. It should be noted that the aforementioned possibilities are
not mutually exclusive. For example, Uev1A can recruit Ubc13
to a process that directly promotes tumorigenesis and meanwhile
prevent Ubc13–Mms2-mediated error-free DNA repair.
Conventional selectivity of Ub addition is thought to be
under the direct influence of E3 enzymes, which target specific
substrates. Here, we describe a novel mechanism that regulates
the type and length of Ub chains and potentially the target pro-
teins. Given recent reports that Lys63 chains are involved in di-
verse functions, such as DNA repair (Broomfield et al., 1998),
stress response and immunity (Deng et al., 2000; Wang et al.,
2001; Zhou et al., 2004), neurodegeneration (Doss-Pepe et
al., 2005; Lim et al., 2005), ribosomal activity (Spence et al.,
2000), endocytosis (Galan and Haguenauer-Tsapis, 1997), that
some of them do require Ubc13–Uev (Bothos et al., 2003;
Doss-Pepe et al., 2005), and that additional Uev proteins have
been identified with known or unknown activities (Wong et al.,
2003), our findings shed light on the diversity and complexity
of the ubiquitination pathways.
Materials and methods
Recombinant protein expression and purification
Detailed creation of GST-Ubc13 and GST-Mms2 fusion constructs, their
overexpression, protease cleavage, and purification have been described
previously (McKenna et al., 2001). The GST-Uev1A and GST-Uev1B con-
structs were made by PCR amplification of UEV1A (obtained from Z.J.
Chen, University of Texas Southwestern Medical Center, Dallas, TX) and
UEV1B (CROC1B; obtained from S. Lin, Robert Wood Johnson Medical
School, Piscataway, NJ) cDNA clones; the resulting fragments were
cloned into pGEX6p (GE Healthcare). The GST-Ubc13K92R construct was
created by site-directed mutagenesis and the GST-Uev1A 30 construct
was made by PCR amplification that removes the NH2-terminal 30-aa cod-
ing region from Uev1A. Each cloned insert was confirmed by DNA se-
quencing before further analysis. Fusion protein overexpression and purifi-
cation were performed in a manner similar to that of GST-Ubc13 and
GST-Mms2 (McKenna et al., 2001).
GST pull-down
GST pull-downs were performed using MicroSpin GST Purification Mod-
ules (GE Healthcare). 500  l of bacterial crude cell extract containing
GST-Mms2, GST-Uev1A, or GST-Uev1B was loaded and incubated in the
purification module for 1 h at 4 C with gentle rocking. The module was
then washed three times with 500  l PBS (140 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, and 1.8 mM KH2PO4, pH 7.3); 30  g of purified
Ubc13 in PBS was added and the incubation was continued for another
hour at 4 C. The module was washed again three times with 500  l PBS,
and then 80  l of reduced glutathione buffer (10 mM glutathione in 50 mM
Tris-HCl, pH 8.0) was added to elute MicroSpin module-bound proteins.
The elution samples were subjected to SDS-PAGE analysis.
Yeast two-hybrid analysis
The hMMS2, UEV1A, and UEV1B coding regions without stop codons
were PCR amplified as BamHI–SalI fragments and cloned into pG4BD-1
(received from R.B. Brazas, University of California, San Francisco, San
Francisco, CA) as COOH-terminal fusions to Gal4BD. The UBC13-coding
region was PCR amplified as an EcoRI–SalI fragment and cloned into
pGAD424 (CLONTECH Laboratories, Inc.) as an NH2-terminal fusion to
Gal4AD.
Yeast cells were grown in either rich YPD or synthetic SD minimal
media at 30 C as described previously (Sherman et al., 1983) and were
transformed with DNA by a LiAc protocol (Ito et al., 1983). Yeast strain
PJ69-4A (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4  gal80 
LYS2::GAL1-HIS3 GAL2-ADE2 met::GAL7-lacZ; received from P. James,
University of Wisconsin, Madison, WI) was cotransformed with pG4BD-1–
and pGAD424-based constructs, and the transformants were selected on
SD-Trp-Leu plates. At least five independent transformants were picked
from each plate and replicated onto SD-Trp-Leu-Ade to detect activation of
the PGAL2-ADE2 reporter gene or onto SD-Trp-Leu-His supplemented with
various concentrations of 3-aminotriazole to measure activation of the
PGAL1-HIS3 reporter gene.
Functional analysis of human genes in yeast
A wild-type haploid S. cerevisiae strain, HK580-10D (MAT ade-1 can1-
100 his3 11,15 leu2-3, 112 trp1-1 ura3-1), was received from H. Klein
(New York University, New York, NY) and used as the recipient to delete
the entire MMS2 open reading frame by a one-step gene replacement
method (Rothstein, 1983) using an mms2 ::HIS3 cassette generated
through PCR amplification as previously described (Xiao et al., 1999). The
resulting mms2  strain, WXY903, was transformed with two-hybrid plas-
mids carrying hMMS2, UEV1A, and UEV1B genes.
The gradient plate assay was performed as previously described
(Xiao et al., 2000) to a semiquantitative measurement of relative MMS
sensitivity.
mAb preparation
Recombinant human Ubc13 and Mms2 proteins were emulsified in Freund’s
incomplete adjuvant. Immediately before i.p. injection of BALB/c mice,
the emulsion was dispersed with an equal volume of PBS containing 2%
Tween 80 (injection volume per mouse of 0.8 ml). Repeat injections of
antigen were given at minimum intervals of 3 wk over several months.
Fusion cells were screened for secretion of a mAb with reactivity to ei-
ther Ubc13 or Mms2 using standard enzyme immunoassay techniques
in 96-well plates. Hybridomas 4E11 and 2H11 were isolated based on
their ability to secrete mAbs recognizing Ubc13 and Mms2, respec-
tively. Hybridoma cells ( 10
6) were injected into the peritoneal cavity
of BALB/c mice that had received an i.p. injection of 0.3 ml of Freund’s
incomplete adjuvant 24 h before. Ascites fluid was collected as the
mAb source.
Western blot analysis
Mouse NIH 3T3 cells were grown to log phase and lysed in Dulbecco’s
PBS (150 mM NaCl, 10 mM Na2HPO4, and 10 mM NaH2PO4, pH 7.4)
with 1% SDS and the protease inhibitor cocktail for mammalian cells
(Sigma-Aldrich). Total protein concentration was determined by the Brad-
ford method using a commercial reagent from Bio-Rad Laboratories. Cell
extracts or purified proteins were electrophoresed in 12% SDS-PAGE gels,
transferred to PVDF membrane, incubated with mAb and a biotin-conju-
gated goat anti–mouse IgG secondary antibody (Sigma-Aldrich), followed
by incubation with Streptavidin-HRP and DAB plus hydrogen peroxide for
color development.
Constructs to express myc-tagged proteins
MMS2,  UEV1A, and UEV1A 30 open reading frames without stop
codons were PCR-amplified as BamHI–XhoI fragments and then cloned
into the BamHI–XhoI sites of pcDNA3.1/Myc-His( )A (Invitrogen) so
that the genes of interest are under the control of a CMV constitutive
promoter and fused in frame with the myc-His6 coding region at the
COOH terminus.
RNAi and siRNA designs
RNAi constructs were created by cloning double-stranded oligonucleotides
at XbaI and BbsI sites of the plasmid vector mU6pro (a gift from D. Turner,
University of Michigan, Ann Arbor MI) as described previously (Yu et al.,
2002). Double-stranded siRNAs were synthesized with 3 dTdT overhangs
by Dharmacon. They were designed to recognize the target sequences as
depicted in Fig. S3.JCB • VOLUME 170 • NUMBER 5 • 2005 754
Cell culture, transfection, and treatments
Human and mouse cell lines were routinely grown in DME (Sigma-Aldrich)
containing 4.5 g glucose and 10% horse serum (Invitrogen), with sodium
bicarbonate reduced to 2.1 g/liter, in a humidified 5% CO2 incubator.
For transfection experiments, 50  l of serum-free DME containing  2  g
DNA and 1  l Lipofectamine 2000 reagent (Invitrogen) was added to
log-phase cells grown on 11   22-mm coverslips containing 100  l of
complete growth medium. After a 16-h incubation, the coverslips were re-
turned to complete growth media and analyzed as specified. It was esti-
mated that typical transfection efficiency was  10% using pcDNA3.1-
derived constructs and  90% using RNAi constructs. For DNA damage
treatment, log-phase cells were incubated continuously with CPT, followed
by washing and immunocytochemistry (ICC). Microglia were isolated from
newborn CD1 mice by aseptically pressing neopalia cleaned of meninges
through 70- m nitex mesh (BD Biosciences) and subsequently cultured in
DME (high glucose) plus 10% horse serum as described previously (Hao et
al., 1991). After 12-d culture, they were exposed to LPS and processed
for ICC.
ICC methods
For routine ICC, cells were fixed in 4% formaldehyde in Dulbecco’s PBS
for 30 min, permeabilized by treating with 0.5% Triton X-100 for 5 min,
and treated with a blocking solution containing 5% horse serum and 2%
skim milk in PBS for 30 min. Primary antibodies used in this study include
rabbit anti-Mre11 (1:200; Oncogene Research Products), rabbit anti-
Rad51 (1:100; Santa Cruz Biotechnology, Inc.), mAb 2H11 (1:100),
mAb 4E11 (1:100), mAb 9E10 (1:400; Sigma-Aldrich), Alexa546-conju-
gated mouse anti-BrdU (1:400; Molecular Probes), and rabbit anti-myc
(1:400; Santa Cruz Biotechnology, Inc.). The green fluorescing Alexa488–
conjugated anti–mouse (1:3,000; Molecular Probes) and the red fluoresc-
ing Alexa546-conjugated anti–rabbit (1:2,000; Molecular Probes) anti-
bodies were used as secondary antibodies. The secondary antibody solu-
tion also contained 2  g/ml DAPI to visualize the nucleus. Both primary
and secondary antibodies were diluted in blocking solution and applied
to cells for 30 min, each followed by three rinses with PBS over 30 min.
The coverslips were then mounted in PBS and observed using an inverted
fluorescence microscope (model IX70; Olympus) fitted with the appropri-
ate filters. Digital images were taken using an RT Slider “Spot” camera
and associated software (Diagnostic Instruments). Statistical data were
compiled and analyzed using Microsoft Excel and GraphPad QuickCalcs
Software (GraphPad Software, Inc.).
To visualize the incorporation of BrdU into DNA, cells were treated
with 50  g/ml DNase-free RNase A immediately after the permeabiliza-
tion step, and the DNA was then denatured by treating cells with 2 N HCl
for 15 min at 65 C before the blocking step. To differentiate the mouse
mAbs 4E11 and 2H11 from mouse anti-BrdU, a modified procedure was
developed. After the secondary Alexa488 anti–mouse antibody was ap-
plied to identify 4E11 and 2H11, coverslips were rinsed thoroughly (six
changes of PBS over 1 h). The cells were again blocked by incubating
with 2% normal mouse serum for 30 min to obstruct unoccupied anti–
mouse Fab regions of bound Alexa488 anti–mouse antibody. Alexa546
anti-BrdU was then applied at a 1:400 dilution for 15 min. To visualize
damage-induced nuclear foci (Tomilin et al., 2001), in situ cell fraction-
ation was performed before fixation by treating cells with 0.4% NP-40 in
PBS for 3.5 min with gentle agitation.
NF- B luciferase reporter and NEMO ubiquitination assays
HEK 293T cells were plated in 6-well plates 18 h before transfection. For
siRNA delivery, cells were transfected with 25 nmol of the indicated
siRNA, using Lipofectamine 2000 (Invitrogen). 24 h after the first transfec-
tion, the cells were transfected again with the same amount of siRNA to-
gether with the indicated expression plasmids. Approximately 36 h after
the second transfection, the cells were collected and used for different ex-
periments. NF- B reporter activity was measured using a Dual-Luciferase
Reporter Assay System (Promega) according to the manufacturer’s proto-
col. Immunoblot analysis of NEMO ubiquitination was performed as de-
scribed previously (Zhou et al., 2004).
In vitro ubiquitination assay
A 0.5-ml conjugation reaction containing 20 nM Uba1, 2.5  M 
35S-
labeled Ub, and 250 nM Ubc13 in an ATP cocktail (10 mM Hepes, pH
7.5, 5 mM MgCl2, 5 mM ATP, and 0.6 U/ml inorganic phosphatase)
were incubated at 30 C for 90 min. The concentration of each component
is noted in the figure legends. Reactions were terminated by the addition
of TCA to a final concentration of 10% and processed for a 12% SDS-
PAGE analysis by autoradiography.
Image acquisition and processing
All photographic images were taken through a microscope (model IX70;
Olympus) with a camera (SPOT RT Slider; Diagnostic Instruments) at RT.
Fluorochromes used include Alexa488 (green; Molecular Probes), Alexa-
546 (red; Molecular Probes), and DAPI (blue; Sigma-Aldrich). For Figs. 5
and 7, an LC PlanFL 40 /0.60 (air) objective (Olympus) was used. For
Fig. 4 and Fig. S2, an UPlanFLN 60 /1.25 oil immersion objective
(Olympus) was used. Images were acquired using Image-Pro Plus version
4.1 software and compiled using Adobe Photoshop version 6. In each
plate, photographs were cropped and each Fluorochrome adjusted iden-
tically for brightness and contrast to represent the observed images. In
Fig. 7, the cyan channel was adjusted identically in all panels to accentu-
ate the merged layer.
Online supplemental material
Fig. S1 shows quantitative analysis of nuclear foci–containing cells after
CPT treatment. Fig. S2 shows cellular localization of Mms2-myc and Uev1-
myc proteins. Fig. S3 shows RNAi and siRNA sequences. Online supple-
mental material is available at http://www.jcb.org/cgi/content/full/
jcb.200502113/DC1.
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